SubHero Banner
Text

Buprenorphine-containing transmucosal drugs – Safety update

 On January 12, 2022, the FDA announced a warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental issues.

Download PDF